Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Albshesh, Ahmad, Bannon, Lian, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R., Tepes, Katja, Pugliese, Daniela, Savarino, Edoardo V., Zittan, Eran, Drobne, David, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro, Lobaton, Triana, Maharshak, Nitsan, Yanai, Henit, Ben-Horin, Shomron, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/
https://www.ncbi.nlm.nih.gov/pubmed/37048587
http://dx.doi.org/10.3390/jcm12072503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/
https://www.ncbi.nlm.nih.gov/pubmed/37048587
http://dx.doi.org/10.3390/jcm12072503

Ejemplares similares